Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)

NCT04205812 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04205812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 11, 2020
Completion date
May 28, 2026
Enrollment
583 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic nonsquamous non-small cell lung cancer, metastatic squamous non-small cell lung cancer